Determining whether Coherus BioSciences (NASDAQ: CHRS) represents a good buy depends heavily on an investor's risk appetite and confidence in small-cap biotechnology equities. Proponents of the stock point to its innovative oncology pipeline, established commercial product lines, and strategic partnerships as strong long-term upside drivers. Conversely, conservative analysts highlight persistent net losses, high operational burn rates, and market volatility as factors requiring caution, suggesting that thorough due diligence is essential before investing.